Früherkennung von Typ-1-Diabetes durch Inselautoantikörper-Screening - ein Positionspapier der Fr1da Plex -Projektleiter und -Schulungszentren, des BVKJ Bayern und PaedNetz Bayern eV.

Peter Achenbach; Reinhard Berner; Ezio Bonifacio; Susanne Brämswig; Sonja Braig; Desiree Dunstheimer; Uwe Ermer; Dominik Ewald; Gita Gemulla; Julia Hauer; Florian Haupt; Gabi Haus; Michael Hubmann; Sandra Hummel; Michael Kandler; Olga Kordonouri; Karin Lange; Otto Laub; Anja Lorrmann; Nicole Nellen-Hellmuth; Marina Sindichakis; Thekla Von Dem Berge; Katharina Warncke; Leonie Weber; Christiane Winkler; Philip Wintermeyer; Anette Gabriele Ziegler

doi:10.1055/a-2320-2859

Früherkennung von Typ-1-Diabetes durch Inselautoantikörper-Screening - ein Positionspapier der Fr1da ^Plex -Projektleiter und -Schulungszentren, des BVKJ Bayern und PaedNetz Bayern eV.

Peter Achenbach, Reinhard Berner, Ezio Bonifacio, Susanne Brämswig, Sonja Braig, Desiree Dunstheimer, Uwe Ermer, Dominik Ewald, Gita Gemulla, Julia Hauer, Florian Haupt, Gabi Haus, Michael Hubmann, Sandra Hummel, Michael Kandler, Olga Kordonouri, Karin Lange, Otto Laub, Anja Lorrmann, Nicole Nellen-HellmuthMarina Sindichakis, Thekla Von Dem Berge, Katharina Warncke, Leonie Weber, Christiane Winkler, Philip Wintermeyer, Anette Gabriele Ziegler

Research output: Contribution to journal › Article › peer-review

Abstract

This position paper is based on the authors' many years of clinical experience and basic science research on the diagnosis and treatment of children and adolescents with a presymptomatic early stage of type 1 diabetes. The benefits as well as potential disadvantages of early detection of type 1 diabetes by islet autoantibody screening are critically discussed. In addition, the perspectives of delaying the onset of the clinical metabolic disease through treatment with teplizumab are addressed. Today, we see the chance of a relevant improvement in the therapeutic options and life perspectives of affected children and adolescents. Important next steps for the implementation of islet autoantibody screening in Germany are the training of pediatricians who should inform families about the screening, the establishment of a few transregional laboratories that carry out the test, and the expansion of regional capacities for the training and care of children with an early stage of type 1 diabetes.

Original language	German
Journal	Gesundheitswesen
DOIs	https://doi.org/10.1055/a-2320-2859
State	Accepted/In press - 2023
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1055/a-2320-2859

Cite this

Achenbach, P., Berner, R., Bonifacio, E., Brämswig, S., Braig, S., Dunstheimer, D., Ermer, U., Ewald, D., Gemulla, G., Hauer, J., Haupt, F., Haus, G., Hubmann, M., Hummel, S., Kandler, M., Kordonouri, O., Lange, K., Laub, O., Lorrmann, A., ... Ziegler, A. G. (Accepted/In press). Früherkennung von Typ-1-Diabetes durch Inselautoantikörper-Screening - ein Positionspapier der Fr1da ^Plex -Projektleiter und -Schulungszentren, des BVKJ Bayern und PaedNetz Bayern eV. Gesundheitswesen. https://doi.org/10.1055/a-2320-2859

@article{38521e6618ee4477b21470c0fe64843a,

title = "Fr{\"u}herkennung von Typ-1-Diabetes durch Inselautoantik{\"o}rper-Screening - ein Positionspapier der Fr1da Plex -Projektleiter und -Schulungszentren, des BVKJ Bayern und PaedNetz Bayern eV.",

abstract = "This position paper is based on the authors' many years of clinical experience and basic science research on the diagnosis and treatment of children and adolescents with a presymptomatic early stage of type 1 diabetes. The benefits as well as potential disadvantages of early detection of type 1 diabetes by islet autoantibody screening are critically discussed. In addition, the perspectives of delaying the onset of the clinical metabolic disease through treatment with teplizumab are addressed. Today, we see the chance of a relevant improvement in the therapeutic options and life perspectives of affected children and adolescents. Important next steps for the implementation of islet autoantibody screening in Germany are the training of pediatricians who should inform families about the screening, the establishment of a few transregional laboratories that carry out the test, and the expansion of regional capacities for the training and care of children with an early stage of type 1 diabetes.",

author = "Peter Achenbach and Reinhard Berner and Ezio Bonifacio and Susanne Br{\"a}mswig and Sonja Braig and Desiree Dunstheimer and Uwe Ermer and Dominik Ewald and Gita Gemulla and Julia Hauer and Florian Haupt and Gabi Haus and Michael Hubmann and Sandra Hummel and Michael Kandler and Olga Kordonouri and Karin Lange and Otto Laub and Anja Lorrmann and Nicole Nellen-Hellmuth and Marina Sindichakis and {Von Dem Berge}, Thekla and Katharina Warncke and Leonie Weber and Christiane Winkler and Philip Wintermeyer and Ziegler, {Anette Gabriele}",

year = "2023",

doi = "10.1055/a-2320-2859",

language = "Deutsch",

journal = "Gesundheitswesen",

issn = "0941-3790",

publisher = "Georg Thieme Verlag",

}

Achenbach, P, Berner, R, Bonifacio, E, Brämswig, S, Braig, S, Dunstheimer, D, Ermer, U, Ewald, D, Gemulla, G, Hauer, J, Haupt, F, Haus, G, Hubmann, M, Hummel, S, Kandler, M, Kordonouri, O, Lange, K, Laub, O, Lorrmann, A, Nellen-Hellmuth, N, Sindichakis, M, Von Dem Berge, T, Warncke, K, Weber, L, Winkler, C, Wintermeyer, P & Ziegler, AG 2023, 'Früherkennung von Typ-1-Diabetes durch Inselautoantikörper-Screening - ein Positionspapier der Fr1da ^Plex -Projektleiter und -Schulungszentren, des BVKJ Bayern und PaedNetz Bayern eV.', Gesundheitswesen. https://doi.org/10.1055/a-2320-2859

TY - JOUR

T1 - Früherkennung von Typ-1-Diabetes durch Inselautoantikörper-Screening - ein Positionspapier der Fr1da Plex -Projektleiter und -Schulungszentren, des BVKJ Bayern und PaedNetz Bayern eV.

AU - Achenbach, Peter

AU - Berner, Reinhard

AU - Bonifacio, Ezio

AU - Brämswig, Susanne

AU - Braig, Sonja

AU - Dunstheimer, Desiree

AU - Ermer, Uwe

AU - Ewald, Dominik

AU - Gemulla, Gita

AU - Hauer, Julia

AU - Haupt, Florian

AU - Haus, Gabi

AU - Hubmann, Michael

AU - Hummel, Sandra

AU - Kandler, Michael

AU - Kordonouri, Olga

AU - Lange, Karin

AU - Laub, Otto

AU - Lorrmann, Anja

AU - Nellen-Hellmuth, Nicole

AU - Sindichakis, Marina

AU - Von Dem Berge, Thekla

AU - Warncke, Katharina

AU - Weber, Leonie

AU - Winkler, Christiane

AU - Wintermeyer, Philip

AU - Ziegler, Anette Gabriele

PY - 2023

Y1 - 2023

N2 - This position paper is based on the authors' many years of clinical experience and basic science research on the diagnosis and treatment of children and adolescents with a presymptomatic early stage of type 1 diabetes. The benefits as well as potential disadvantages of early detection of type 1 diabetes by islet autoantibody screening are critically discussed. In addition, the perspectives of delaying the onset of the clinical metabolic disease through treatment with teplizumab are addressed. Today, we see the chance of a relevant improvement in the therapeutic options and life perspectives of affected children and adolescents. Important next steps for the implementation of islet autoantibody screening in Germany are the training of pediatricians who should inform families about the screening, the establishment of a few transregional laboratories that carry out the test, and the expansion of regional capacities for the training and care of children with an early stage of type 1 diabetes.

AB - This position paper is based on the authors' many years of clinical experience and basic science research on the diagnosis and treatment of children and adolescents with a presymptomatic early stage of type 1 diabetes. The benefits as well as potential disadvantages of early detection of type 1 diabetes by islet autoantibody screening are critically discussed. In addition, the perspectives of delaying the onset of the clinical metabolic disease through treatment with teplizumab are addressed. Today, we see the chance of a relevant improvement in the therapeutic options and life perspectives of affected children and adolescents. Important next steps for the implementation of islet autoantibody screening in Germany are the training of pediatricians who should inform families about the screening, the establishment of a few transregional laboratories that carry out the test, and the expansion of regional capacities for the training and care of children with an early stage of type 1 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=85193536922&partnerID=8YFLogxK

U2 - 10.1055/a-2320-2859

DO - 10.1055/a-2320-2859

M3 - Artikel

AN - SCOPUS:85193536922

SN - 0941-3790

JO - Gesundheitswesen

JF - Gesundheitswesen

ER -